VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HITHealth In Tech, Inc.
$1.04$56M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. HIT
  4. Financial Ratios

Health In Tech, Inc. (HIT) Financial Ratios

Latest Ratios: P/E Ratio 52.0x · EV/EBITDA 19.9x · ROE 8.4%. (2022–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

HIT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022
Market Cap$56M$92M$288M——
Enterprise Value$48M$84M$280M——
P/E Ratio →52.0079.50435.77——
P/S Ratio1.682.7514.76——
P/B Ratio3.515.3721.84——
P/FCF——225.51——
P/OCF17.8629.30132.17——

P/E links to full P/E history page with 30-year chart

HIT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022
EV / Revenue—2.5314.37——
EV / EBITDA19.9534.70182.87——
EV / EBIT31.7050.34202.30——
EV / FCF——219.52——

HIT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022
Gross Margin62.8%62.8%79.2%88.0%94.2%
Operating Margin4.6%4.6%5.1%17.7%3.6%
Net Profit Margin3.8%3.8%3.4%12.9%1.4%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022
ROE8.4%8.4%7.0%65.9%5.6%
ROA6.6%6.6%4.9%12.4%0.3%
ROIC15.2%15.2%13.4%86.9%62.6%
ROCE9.7%9.7%9.7%60.1%4.5%

HIT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022
Debt / Equity0.010.010.020.310.22
Debt / EBITDA0.060.060.140.511.54
Net Debt / Equity—-0.44-0.58-0.08-0.83
Net Debt / EBITDA-3.10-3.10-4.99-0.13-5.70
Debt / FCF——-5.99-1.30—
Interest Coverage——2.801668.5944.97

Net cash position: cash ($8M) exceeds total debt ($139812)

HIT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022
Current Ratio3.133.135.061.431.06
Quick Ratio3.133.135.061.431.06
Cash Ratio1.491.493.680.510.06
Asset Turnover—1.441.241.660.20
Inventory Turnover—————
Days Sales Outstanding—8.2840.2174.6561.80

HIT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022
Dividend Yield—————
Payout Ratio—————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022
Earnings Yield1.9%1.3%0.2%——
FCF Yield——0.4%——
Buyback Yield0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%——
Shares Outstanding—$58M$54M$54M$54M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Margin compression from scaling

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Pricing Amidst Operational Uncertainty

Based on current market data, HIT trades at a P/S multiple of 1.68 and an EV/EBITDA of 19.95, suggesting that investors are pricing in significant future growth despite the company's recent shift toward negative operating margins and the absence of a clear path to near-term profitability.

The valuation appears to reflect a high-growth SaaS premium, yet the underlying financial reality of a 4.59% operating margin suggests that the market may be overestimating the scalability of the current reference-based pricing model. Investors should monitor whether the company can justify these multiples through sustained margin expansion, as the current P/E of 52.00 implies a growth trajectory that may be difficult to maintain if provider resistance continues to escalate.

Capital Efficiency Decay During Expansion

As reported in financial statements, ROIC has deteriorated from a peak of 19.5% in 2023Q4 to -15.4% in 2026Q1, indicating that the company's aggressive investment in market penetration is currently failing to generate returns that exceed the cost of capital required to sustain its operational footprint.

The sharp decline in ROIC suggests that the capital allocated toward scaling the eDIYBS platform is not yet yielding the expected efficiency gains, likely due to the high-touch nature of managing captive insurance networks. This trend warrants further investigation into whether the current capital allocation strategy is prioritizing growth at the expense of long-term value creation for shareholders.

Working Capital Drag on Operations

According to historical data, asset turnover has remained stagnant near 0.34x, while the volatility in DSO, which reached 55 days in 2025Q2, suggests that the company is facing increasing friction in converting its service-based revenue into actual cash inflows from its small-to-medium business client base.

The inability to improve asset turnover despite rapid revenue growth implies that the business model remains inherently labor-intensive rather than purely software-driven. This inefficiency, combined with the lack of clear DPO trends, suggests that the company may be struggling to leverage its position with suppliers, potentially limiting its ability to optimize working capital during this aggressive scaling phase.

Liquidity Buffer Under Scaling Pressure

Based on the most recent quarterly filings, the current ratio of 3.13 provides a superficial sense of security, yet the absolute cash position of $7.6 million appears increasingly vulnerable given the company's negative free cash flow margin of 42.0% observed in the first quarter of 2026.

While the company maintains a clean balance sheet with minimal debt, the rapid depletion of cash reserves to fund operations suggests that the current liquidity position may be insufficient to support long-term growth without external financing. Investors should monitor the cash burn rate closely, as any further deterioration in liquidity could force management to seek dilutive capital raises to maintain its competitive position.

Misapplication of SaaS Valuation Multiples

The market commonly misapplies standard SaaS P/S multiples to HIT, which obscures the reality that a significant portion of revenue is derived from high-touch, advocacy-heavy claims processing rather than purely automated software subscriptions, leading to an overestimation of the company's long-term operating leverage potential.

By treating HIT as a pure-play software firm, analysts likely overlook the structural costs associated with provider network management and the legal complexities of reference-based pricing. A more appropriate metric would be to adjust for the high cost of revenue and focus on the contribution margin per captive member, which would provide a more accurate assessment of the company's true earning power.

Download Financial Ratios Data

Includes 30+ ratios · 4 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HIT — Frequently Asked Questions

Quick answers to the most common questions about buying HIT stock.

What is Health In Tech, Inc.'s P/E ratio?

Health In Tech, Inc.'s current P/E ratio is 52.0x. The historical average is 79.5x.

What is Health In Tech, Inc.'s EV/EBITDA?

Health In Tech, Inc.'s current EV/EBITDA is 19.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.7x.

What is Health In Tech, Inc.'s ROE?

Health In Tech, Inc.'s return on equity (ROE) is 8.4%. The historical average is 21.7%.

Is HIT stock overvalued?

Based on historical data, Health In Tech, Inc. is trading at a P/E of 52.0x. Compare with industry peers and growth rates for a complete picture.

What are Health In Tech, Inc.'s profit margins?

Health In Tech, Inc. has 62.8% gross margin and 4.6% operating margin.

How much debt does Health In Tech, Inc. have?

Health In Tech, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.